41 results about "Mononucleosis" patented technology

Vital mononucleosis listeria RT-PCR fast inspecting reagent kit and its method are disclosed. The process is carried out by taking mRNA of mononucleosis listeriolysin gene hlyA as target, extracting sample RNA, RT-PCR amplification reacting and electrophoresis inspecting. It is fast, has better sensitivity and operability. It can be used in environmental inspection, food production and commodity quarantine.

The invention relates to the field of gene engineering, and aims to provide a construction method and application of attenuated Listeria monocytogenes. A Listeria monocytogenes wild strain EGD-e is used as a construction parent, and asparagine at the 478th site and valine at the 479th site of an hly gene are respectively mutated into alanine without containing plasmids; the finally obtained attenuated strain is named as Lemo-C07, the preservation number of the attenuated strain is CGMCC 18647, and the preservation institution is China General Microbiological Culture Collection Center. The attenuated strain of Listeria monocytogenes can be used as a live vaccine treatment carrier or an immunologic adjuvant; after amino acid site-specific mutagenesis of the key sites N478 and V479 of the Listeria monocytogenes virulence gene hly, the toxicity of the Listeria monocytogenes is greatly reduced (reaching a safety level), but very good immunogenicity is still retained. As direct mutation is carried out on the Listeria monocytogenes genome, the Listeria monocytogenes does not contain resistance plasmids, the biosafety is met, and the growth of the Listeria monocytogenes is not influenced by the loss of the plasmids.

Vital mononucleosis listeria RT-PCR fast inspecting reagent kit and its method are disclosed. The process is carried out by taking mRNA of mononucleosis listeriolysin gene hlyA as target, extracting sample RNA, RT-PCR amplification reacting and electrophoresis inspecting. It is fast, has better sensitivity and operability. It can be used in environmental inspection, food production and commodity quarantine.

The present invention relates to compositions comprising a lipophilic local anaesthetic, preferably bupivacaine or a pharmaceutically active salt thereof, which are formulated for local administration to the mouth or throat of a subject. The compositions are useful in the treatment or alleviation of pain, burning or xerostomia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa or for use in providing local anesthesia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa. In particular in the treatment of pain, burning or xerostomia, which is caused by a disease such as oral mucositis, Burning Mouth Syndrome, Sjogren's syndrome, xerostomia, periodontitis, toothache, tonsillectomy, throat infection or mononucleosis, canker sores and aphthous stomatitis.

The invention provides spring water monoucleosis for degrading alflatoxin B1 and ochratoxin A and application of the spring water mononucleosis and particularly provides a strain of difunctional efficient degrading bacteria (Silanimonas sp.) CW282 and application thereof in degrading low-pollution-concentration alflatoxin B1 and ochratoxin A. Compared with existing aflatoxin degrading bacteria, the strain CW282 can achieve excellent degrading effects under the condition of low-concentration toxin pollution. Under the condition of liquid fermentation, in a fermentation culture solution containing alflatoxin B1 and ochratoxin A with the final concentration being 20 micrograms per liter, the degrading rate of the strain CW282 on ochratoxin A is 70.7% in 24 h and reaches 95.6% in 48 h; the degrading rate of the strain CW282 on alflatoxin B1 is 86.9% in 24 h and reaches 91.3% in 48 h. When the strain CW282 is used for treating fodder (the final concentration is 20 micrograms per kg) polluted by toxins, the degrading rate on ochratoxin A is 53.2% in 48 h, and the degrading rate on alflatoxin B1 is 58.3% in 48 h. The strain CW282 has substantive application value and significance on the application aspects of food and feed biological detoxification.

A Lister bacterium and fast test reagent kit are disclosed. It consists of two freezing tubes containing different ingredients, 100 PCR reactive tubes and test specifications, the freezing tubes include TaqDNApolymerase, 10Xbuffer, dNTP, primer LM, LN, LS, LVSW, LGU, Ld, Lmo0038-1 and Lmo0038-2 and cracking buffer solution, positive control solution and diluting solution. The lowest testing limitreaches to 102FU / mL is correct, specific and sensitive.

The invention relates to the technical field of medical diagnosis, and in particular relates to an FISH detection probe for detecting an EB virus of an infectious mononucleosis patent. The probe is obtained by marking a BamHI-W segment of the EB virus; the nucleotide sequence of the BamHI-W segment is as shown in an EBV genome 13232-16189. Compared with a conventional infectious mononucleosis detection method, the sensitivity and specificity of the probe are higher than the copy number of viruses of EBV, and the viruses are accurately positioned in cells, and the viral load can be also quietly intuitively judged.

The invention discloses a method for performing high-flux quick detection on food-borne pathogens by using a multiplex PCR (polymerase chain reaction) technique. Primers suitable for multiplex PCR are designed according to conserved region sequences of four main food-borne pathogens salmonella, Staphylococcus aureus, Listeria monocytogenes and Escherichia coli O157:H7, and the multiplex PCR technique is utilized to detect the main food-borne pathogens in the agricultural product. The detection method has the advantages of favorable specificity, higher sensitivity and high detection limit (up to 10<3>copies / ml), and is quick and convenient; and after the primers perform non-cross reaction with 8 similar strains, the amplified strip is clear. The primers and multiplex PCR system can be prepared into a kit for quickly detecting food-borne pathogens; and the kit can greatly shorten the time and enhance the detection efficiency.

Anti-Epstein Barr Virus (EBV) antibodies and vaccines are described herein. The antibodies and vaccines can be used to treat and / or reduce the risk of EBV infection and to treat and / or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.

The present invention provides EBNA1 inhibitors, and / or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and / or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and / or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and / or lytic EBV infection.

The invention discloses a multi-PCR detecting method capable of detecting mononuclear hyperplasia, staphylococcus aureus and enterococcus faecium simultaneously. The multi-PCR detecting method capable of simultaneously detecting three pathogenic bacteria, namely, the mononuclear hyperplasia, the staphylococcus aureus and the enterococcus faecium, is established by designing premiers respectively according to the hlyA gene of the mononuclear hyperplasia, the NUC gene of the staphylococcus aureus and the ddl gene of the enterococcus faecium. According to the method, the DNA fragments of the mononuclear hyperplasia, the staphylococcus aureus and the enterococcus faecium can be amplified specifically; the lowest detecting amounts are 1.07 pg, 11.6 pg, and 1.21 pg respectively. The method does not have a cross reaction to other common pathogenic bacteria. The multi-PCR reaction established by the method has the characteristics of high specificity and high sensitivity; a convenient, quick and accurate method is provided for quick detection, authentication and epidemiological investigation of the mononuclear hyperplasia, the staphylococcus aureus and the enterococcus faecium in clinical work.

The invention discloses a pharmaceutical composition for treating infectious mononucleosis in children. The pharmaceutical composition is composed of Diaphragm diaphylla extract and Ainaxiang extract in a weight ratio of (2-4):1 composition. The present invention finds for the first time that the combined use of Diaozhumei extract and Ainaxiang extract can have a very good therapeutic effect on infectious mononucleosis in children, and can clear away heat and relieve fire, detoxify and sore throat, and reduce phlegm The function of dispelling stagnation can restore the detoxification and detoxification functions of lymph nodes and liver, fundamentally remove EB virus, and then improve blood and respiratory circulation, so that the blood system and respiratory system can restore their self-regulating functions.

The invention relates to the use of an EBV membrane antigen or derivative thereof in combination with a suitable adjuvant in the manufacture of a vaccine for the prevention of infectious mononucleosis (IM), and to vaccine compositions suitable for prevention of IM.

The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and / or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.